San Francisco, California, United States In 2001 was created Latterell Venture Partners, which is appeared as VC. The company was established in North America in United States. The main department of described VC is located in the San Francisco.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Latterell Venture Partners, startups are often financed by DeNovo Ventures, Morgenthaler Ventures, Adams Street Partners. The meaningful sponsors for the fund in investment in the same round are The Vertical Group, Morgenthaler Ventures, Adams Street Partners. In the next rounds fund is usually obtained by DeNovo Ventures, Adams Street Partners, Morgenthaler Ventures.
Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. The fund has exact preference in some founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low. Among the most popular portfolio startups of the fund, we may highlight Pulmonx, TetraLogic Pharmaceuticals, Neuraltus Pharmaceuticals. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Analytics, Pharmaceutical.
This organization was formed by Larry Lasky, Pat Latterell. Besides them, we counted 2 critical employees of this fund in our database.
The high activity for fund was in 2012. The top amount of exits for fund were in 2016. The usual things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 1 percentage points more often commits exit comparing to other companies. Comparing to the other companies, this Latterell Venture Partners performs on 1 percentage points more the average number of lead investments. The fund is constantly included in 2-6 investment rounds annually.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Access Private Equity | Houston, Texas, United States |
| Alberta Innovates | Alberta, Canada, Edmonton |
| AMC Networks | New York, New York, United States |
| Donghai Securities | - |
| Genesis Node Capital | China, Hong Kong, Hong Kong Island |
| Gruschel Ventures | Berlin, Berlin, Germany |
| Huoer Guosi Chuangtou | China, Xinjiang, Yining |
| Jochu Technology | Hsinchu, Taiwan, Taiwan Province |
| Juxiu Capital | China, Hangzhou, Zhejiang |
| Kentucky Co-Investment | - |
| New Energies Invest | - |
| Qiaobei Investment Management Partnership | China, Shanghai |
| Star Bay Partners LP | California, San Francisco, United States |
| The Burtzloff Family Trust | California, United States, Westlake Village |
| Thompson Clive and Partners | - |
| Tongjian Tailite | Beijing, Beijing, China |
| Verdoso Media | - |
| Vestech Partners | Florida, Ocala, United States |
| Yijun Touzi | China, Hangzhou, Zhejiang |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Viracta Therapeutics | $18M | 04 Apr 2017 | California, United States | ||
Aptinyx | $65M | 10 May 2016 | Illinois, United States | ||
PerceptiMed | $5M | 27 Mar 2015 | Mountain View, California, United States | ||
Naurex | $80M | 03 Dec 2014 | Illinois, United States | ||
Transcend Medical | $29M | 02 Apr 2014 | California, United States | ||
Naurex | $38M | 17 Dec 2012 | Illinois, United States | ||
Viracta Therapeutics | $13M | 12 Mar 2012 | California, United States | ||
Neuraltus Pharmaceuticals | $9M | 31 Jan 2012 | Palo Alto, California, United States | ||
Transcend Medical | $16M | 17 Jan 2012 | California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Viracta Therapeutics | $18M | 04 Apr 2017 | California, United States | ||
Aptinyx | $65M | 10 May 2016 | Illinois, United States | ||
PerceptiMed | $5M | 27 Mar 2015 | Mountain View, California, United States | ||
Naurex | $80M | 03 Dec 2014 | Illinois, United States | ||
Transcend Medical | $29M | 02 Apr 2014 | California, United States | ||
Naurex | $38M | 17 Dec 2012 | Illinois, United States | ||
Viracta Therapeutics | $13M | 12 Mar 2012 | California, United States | ||
Neuraltus Pharmaceuticals | $9M | 31 Jan 2012 | Palo Alto, California, United States | ||
Transcend Medical | $16M | 17 Jan 2012 | California, United States |
